Test Price
2,800 AED✅ Home Collection Available
PNPLA6 Gene SPG39 Next-Generation Sequencing (NGS) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين PNPLA6 (SPG39) بتقنية التسلسل الجيني NGS في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Clinical Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited NGS workflow with confirmatory Sanger sequencing.
Premium Logistics: Paid hospital‑grade home collection by DHA‑licensed phlebotomists, ISO certified cold‑chain transport, and VIP mobile phlebotomy service (8 AM – 11 PM).
Post‑Test Clinical Guidance: Complimentary telephonic interpretation session with a clinical geneticist to discuss results and next steps.
Insurance Support: Direct billing verification via WhatsApp at +971 54 548 8731; many UAE policies cover genetic testing for suspected hereditary neurological disorders.
ملخص تنفيذي: فحص جيني متقدم لتشخيص طفرات جين PNPLA6 المسببة للشلل التشنجي الوراثي (SPG39) واعتلالات عصبية نادرة، بتقنية تسلسل الجيل التالي، مع ضمان المطابقة لدليل هيئة الصحة بدبي 2026.
Overview
The PNPLA6 Gene SPG39 Genetic Test identifies pathogenic variants in the entire coding region of the PNPLA6 gene, providing a definitive molecular diagnosis for hereditary spastic paraplegia type 39 and related neurodegenerative conditions such as Boucher‑Neuhäuser and Gordon Holmes syndromes.
يكشف تحليل جين PNPLA6 بتقنية NGS عن التغيرات الجينية المسببة للشلل التشنجي الوراثي من النوع 39 واضطرابات عصبية وراثية نادرة بدقة تشخيصية عالية.
| Feature | Our Test – NGS (PNPLA6) | Traditional Sanger Sequencing |
|---|---|---|
| Variant Detection | >99.9% sensitivity for coding and splice-site variants | ~95% for targeted regions; misses deep intronic/large rearrangements |
| Method | Next‑Generation Sequencing + confirmatory Sanger | Sanger sequencing of individual exons |
| Turnaround Time | 3–4 weeks | 4–6 weeks for full gene |
Physician Insight & Safety Protocol
“We understand that dealing with progressive neurological symptoms can be overwhelming. While this genetic test can offer crucial answers, it must always be interpreted in the context of your full clinical picture, family history, and neurological examination. Please remember that a negative result does not rule out other neurodegenerative disorders, and do not discontinue any prescribed medication without first consulting your treating physician.”
— Dr. PRABHAKAR REDDY, DHA License 61713011, Consultant Neurologist & Clinical Geneticist
Safety & Exclusion Criteria
- Exclusion: Patients with active coagulopathy or severe thrombocytopenia require special collection arrangements.
- ER Red Flags: If you develop sudden vision loss, rapid gait deterioration, or unexplained falls after sample collection, seek emergency evaluation immediately.
- Minors: In compliance with UAE CDS Law 2026, a legal guardian’s consent and genetic counselling are mandatory before testing individuals under 18.
- Data Privacy: All genetic information is protected under UAE PDPL; results are shared solely with authorized clinicians.
Patient FAQ & Clinical Guidance
1. What does the PNPLA6 NGS test detect?
“Snippet: The PNPLA6 gene NGS test detects pathogenic mutations causing hereditary spastic paraplegia type 39 and related syndromes.”
This advanced genomic analysis scans all exons and splice junctions of the PNPLA6 gene. A positive result confirms a diagnosis of SPG39 or other PNPLA6‑related neurodegeneration, enabling targeted symptom management, reproductive counselling, and cascade family screening.
يكشف التحليل عن طفرات جين PNPLA6 المسؤولة عن الشلل التشنجي الوراثي من النوع 39 ومتلازمات عصبية أخرى، ويوجه العلاج والاستشارة الوراثية.
2. How is the sample collected and what preparation is needed?
“Snippet: A simple blood draw or buccal swab is taken at your home, and genetic counselling is advised beforehand.”
Our DHA‑licensed mobile phlebotomy team arrives between 8 AM and 11 PM for a painless venous blood sample, buccal swab, or collection onto an FTA card. No fasting is required. However, a pre‑test genetic counselling session (included) helps build an accurate pedigree and ensures informed consent.
سحب عينة دم أو مسحة فموية منزليًا، مع جلسة استشارة وراثية قبل الفحص لضمان دقة التاريخ العائلي.
3. Is this genetic covered by insurance in the UAE?
“Snippet: Many UAE health plans cover genetic testing for neurological symptoms, and we verify coverage directly via WhatsApp.”
Coverage depends on your policy’s genetic testing provisions, especially when ordered by a consultant neurologist or geneticist. Our team performs real‑time insurance verification through the dedicated line +971 54 548 8731, and we assist with pre‑approval documentation to maximize your benefits.
غالبية خطط التأمين الصحي في الإمارات تغطي فحوصات الجينات لأعراض عصبية، نتحقق من التغطية عبر واتساب.
Federal Decree‑Law No. 41 of 2024 (Art. 87) | UAE CDS Law 2026 (Minors) | UAE PDPL
Licensed by DHA/MOHAP under Facility License 9834453 | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139)
Support/WhatsApp: +971 54 548 8731 | Results & counselling coordination
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians